703 Participants Needed

Combination Therapy for Crohn's Disease

(DUET-CD Trial)

Recruiting at 604 trial locations
SC
Overseen ByStudy Contact
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: Janssen Research & Development, LLC
Must be taking: Biologics
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial is testing a new medication called JNJ-78934804 to see if it works better than two existing treatments for autoimmune conditions. The study will compare their effectiveness over several months.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Is Golimumab safe for treating Crohn's Disease?

Golimumab has been used in patients with Crohn's Disease and ulcerative colitis, showing some safety in humans, but its effectiveness can vary, and close monitoring is recommended. In some cases, patients needed higher doses to maintain the treatment's effect.12345

How is the combination therapy for Crohn's disease with Golimumab, Guselkumab, and JNJ-78934804 different from other treatments?

This combination therapy is unique because it involves Golimumab, which is typically used for ulcerative colitis and not standard for Crohn's disease, and Guselkumab, which targets a different inflammatory pathway (interleukin-23) than traditional treatments. This approach may offer a novel option for patients who do not respond to standard anti-TNF (tumor necrosis factor) therapies.12567

What data supports the effectiveness of the drug combination therapy for Crohn's Disease?

Golimumab, one of the drugs in the combination, has been used off-label for difficult-to-treat Crohn's Disease cases, showing potential as a rescue medication. Additionally, adalimumab, a similar drug targeting tumor necrosis factor, has been effective in inducing and maintaining remission in Crohn's Disease patients, suggesting that similar drugs may also be beneficial.15689

Who Is on the Research Team?

JR

Janssen Research & Development, LLC Clinical Trial

Principal Investigator

Janssen Research & Development, LLC

Are You a Good Fit for This Trial?

This trial is for adults with moderate to severe Crohn's Disease who haven't had success with at least one biologic treatment. They must have been diagnosed at least 3 months prior and meet specific disease activity criteria. Women of childbearing age should comply with contraception requirements. Exclusions include a recent history of cancer, certain infections, or recent surgeries.

Inclusion Criteria

I have Crohn's disease and did not respond well to at least one biologic treatment.
I have been diagnosed with Crohn's disease for at least 3 months.
I have a confirmed diagnosis of moderate to severe Crohn's disease.
See 5 more

Exclusion Criteria

I have or might have an abscess, but if it was drained and treated properly, I can still participate.
I have not had major surgery or bowel resection in the past 6 months.
I have a history of or currently have a chronic infection.
See 3 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either JNJ-78934804, guselkumab, golimumab, or placebo subcutaneously. Participants with inadequate response may be escalated to an active treatment.

48 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Long-term extension (optional)

Participants who are eligible and willing may continue the study intervention they are receiving at Week 44

Long-term

What Are the Treatments Tested in This Trial?

Interventions

  • Golimumab
  • Guselkumab
  • JNJ-78934804
  • Placebo
Trial Overview The study tests the effectiveness of JNJ-78934804 against guselkumab and golimumab in treating Crohn's Disease by week 48. Participants will receive either the experimental drug (JNJ-78934804) or one of the known drugs along with a placebo to compare results.
How Is the Trial Designed?
6Treatment groups
Experimental Treatment
Placebo Group
Group I: Group 6: JNJ-78934804 (Low-dose)Experimental Treatment1 Intervention
Participants will receive JNJ-78934804 dose regimen 3 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.
Group II: Group 5: JNJ-78934804 (Mid-dose)Experimental Treatment1 Intervention
Participants will receive JNJ-78934804 dose regimen 2 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.
Group III: Group 4: JNJ-78934804 (High-dose)Experimental Treatment1 Intervention
Participants will receive JNJ-78934804 dose regimen 1 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.
Group IV: Group 3: GolimumabExperimental Treatment1 Intervention
Participants will receive golimumab dose regimen 1 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.
Group V: Group 2: GuselkumabExperimental Treatment1 Intervention
Participants will receive guselkumab dose regimen 1 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.
Group VI: Group 1: PlaceboPlacebo Group1 Intervention
Participants will receive placebo subcutaneously (SC). All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.

Golimumab is already approved in European Union, United States, Canada for the following indications:

🇪🇺
Approved in European Union as Simponi for:
  • Rheumatoid arthritis
  • Psoriatic arthritis
  • Ankylosing spondylitis
  • Ulcerative colitis
🇺🇸
Approved in United States as Simponi for:
  • Rheumatoid arthritis
  • Psoriatic arthritis
  • Ankylosing spondylitis
  • Ulcerative colitis
🇨🇦
Approved in Canada as Simponi for:
  • Rheumatoid arthritis
  • Psoriatic arthritis
  • Ankylosing spondylitis
  • Ulcerative colitis

Find a Clinic Near You

Who Is Running the Clinical Trial?

Janssen Research & Development, LLC

Lead Sponsor

Trials
1,022
Recruited
6,408,000+
Joaquin Duato profile image

Joaquin Duato

Janssen Research & Development, LLC

Chief Executive Officer since 2022

MBA from ESADE, Master of International Management from Thunderbird School of Global Management

Dr. Jijo James, MD profile image

Dr. Jijo James, MD

Janssen Research & Development, LLC

Chief Medical Officer since 2014

MD from St. Johns Medical College, MPH from Columbia University

Published Research Related to This Trial

In a 52-week study involving 24 patients with Crohn's disease who previously lost response to infliximab, adalimumab demonstrated significant efficacy, with clinical remission rates increasing from 35% at baseline to 58% at week 52.
Adalimumab was well tolerated, with no patients experiencing intolerance and no serious toxicities reported, indicating it is a safe option for maintaining remission in these patients.
Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study.Peyrin-Biroulet, L., Laclotte, C., Bigard, MA.[2015]
Adalimumab, a monoclonal antibody targeting tumor necrosis factor, has been shown to effectively induce clinical response and remission in patients with moderate-to-severe Crohn's disease, based on recent evaluations.
The safety profile of adalimumab appears comparable to other similar treatments, but further long-term studies are necessary to fully assess its efficacy and safety in Crohn's disease management.
Adalimumab for the treatment of Crohn's disease.Papadakis, KA.[2010]
In a retrospective audit of 61 patients with Crohn's disease, adalimumab achieved remission in 57% of patients and maintained an ongoing response rate of 83.6% over an average follow-up of 8 months, indicating its efficacy in real-life settings.
Adverse effects were reported in 23% of patients, with infections being the most common, but only two patients discontinued treatment due to these adverse events, suggesting a generally acceptable safety profile for adalimumab.
Survey on the use of adalimumab as maintenance therapy in Crohn's disease in England and Ireland.Russo, EA., Iacucci, M., Lindsay, JO., et al.[2015]

Citations

Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study. [2015]
Effectiveness and Safety of Golimumab in Treating Outpatient Ulcerative Colitis: A Real-Life Prospective, Multicentre, Observational Study in Primary Inflammatory Bowel Diseases Centers. [2022]
Adalimumab for the treatment of Crohn's disease. [2010]
Survey on the use of adalimumab as maintenance therapy in Crohn's disease in England and Ireland. [2015]
The Efficacy and Safety of Golimumab as Third- or Fourth-Line Anti-TNF Therapy in Patients with Refractory Crohn's Disease: A Case Series. [2022]
Golimumab Therapy in Six Patients With Severe Pediatric Onset Crohn Disease. [2022]
Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study. [2023]
Efficacy and safety of adalimumab for the Crohn's disease: a systematic review and meta-analysis of published randomized placebo-controlled trials. [2022]
Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. [2021]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security